Jazz Pharmaceuticals Overview
- Year Founded
-
2003
- Status
-
Public
- Employees
-
2,800
- Stock Symbol
-
JAZZ
- Investments
-
17
- Share Price
-
$118.24
- (As of Thursday Closing)
Jazz Pharmaceuticals General Information
Description
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Contact Information
- Waterloo Exchange
- Waterloo Road
- Dublin 4
- Ireland
Jazz Pharmaceuticals Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $118.24 | $114.26 | $111.25 - $160.96 | $7.44B | 63M | 666K | $1.23 |
Jazz Pharmaceuticals Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 12,610,041 | 14,946,481 | 13,544,144 | 9,521,342 |
| Revenue | 3,794,392 | 3,659,374 | 3,094,238 | 2,363,567 |
| EBITDA | 813,875 | 544,929 | 718,411 | 653,055 |
| Net Income | 79,954 | (224,060) | (329,668) | 238,616 |
| Total Assets | 11,204,065 | 10,835,255 | 12,298,639 | 6,535,901 |
| Total Debt | 5,793,878 | 5,812,117 | 6,152,906 | 2,249,330 |
Jazz Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Jazz Pharmaceuticals Comparisons
Industry
Financing
Details
000000
000000
Jazz Pharmaceuticals Competitors (11)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Gilead Sciences | Formerly VC-backed | Foster City, CA | 00000 | 000.00 | 000000000 | 000.00 |
| 000000000 00000000 | Formerly VC-backed | Tarrytown, NY | 00000 | 00.000 | 000000000000 | 00.000 |
| 00000 000000000000 | Formerly VC-backed | London, United Kingdom | 00 | 00000 | 000000000 | 00000 |
| 000000000 | Formerly VC-backed | South San Francisco, CA | 00000 | 000.00 | 0000000000 | |
| 0000000 0000000000 | Formerly VC-backed | Lexington, MA | 000 | 00000 | 000000&0 | 00000 |
Jazz Pharmaceuticals Patents
Jazz Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202212641-D0 | Novel compounds | Pending | 31-Aug-2022 | 0000000000 | |
| GB-202203976-D0 | Tricyclic phthalazines and derivatives as sos1 inhibitors | Inactive | 22-Mar-2022 | 0000000000 | |
| AU-2022299418-A1 | Sulfonamide orexin receptor agonists and uses thereof | Pending | 25-Jun-2021 | ||
| AU-2022269811-A1 | Orexin receptor agonists and uses thereof | Pending | 03-May-2021 | 0000000000 | |
| CA-3217403-A1 | Orexin receptor agonists and uses thereof | Pending | 03-May-2021 | C07D498/10 |
Jazz Pharmaceuticals Executive Team (39)
Jazz Pharmaceuticals Board Members (18)
| Name | Representing | Role | Since |
|---|---|---|---|
| Anne O'Riordan | Jazz Pharmaceuticals | Board Member and Member of Audit Committee & Nominating & Corporate Governance Committee | 000 0000 |
| Bruce Cozadd | Jazz Pharmaceuticals | Co-Founder, Chief Executive Officer & Chairman | 000 0000 |
| Catherine Sohn | Self | Board Member and Member of Compensation & Management Development Committee and Science and Medicine Committee | 000 0000 |
| Heather McSharry | Self | Board Member, Member of the Audit Committee & Chairperson of the Nominating & Corporate Governance Committee | 000 0000 |
| Jennifer Cook | Self | Board Member and Chairman of Compensation & Management Development Committee | 000 0000 |
Jazz Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Jazz Pharmaceuticals Investments & Acquisitions (17)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Zymeworks (Zanidatamab) | 21-Dec-2022 | 000000000 | Drug Discovery | ||
| Onera | 29-Jul-2021 | 00000 0000 | 000.00 | Monitoring Equipment | |
| GW Pharmaceuticals | 05-May-2021 | 0000000000 | 00.00 | Biotechnology | 00000 000 |
| SpringWorks Therapeutics (Fatty Acid Amide Hydrolase Inhibitor Program in Stamford, Connecticut) | 26-Oct-2020 | 000000000 | 0000 | Buildings and Property | |
| Cavion | 12-Aug-2019 | Merger/Acquisition | 00000 | Pharmaceuticals | 000000 00 |
Jazz Pharmaceuticals Subsidiaries (3)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Azur Pharma | Pharmaceuticals | Dublin, Ireland | 2006 |
| Cavion | Pharmaceuticals | Charlottesville, VA | 0000 |
| GW Pharmaceuticals | Biotechnology | Cambridge, United Kingdom | 0000 |
Jazz Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated December, 10, 2022
26.26 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,708
Rank
Percentile
Pharmaceuticals
Industry
00 of 884
Rank
Percentile
Biotechnology
Subindustry
00 of 399
Rank
Percentile
Jazz Pharmaceuticals Exits (2)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| EUSA Pharma | 12-Jun-2012 | 000000000000000000 | 00000 | Completed |
|
| Prialt | 05-May-2010 | Merger/Acquisition | 00000 | Completed |